Jack Elands

Dr. Jack Elands is the co-founder and Chief Executive Officer of Emergence Therapeutics and a member of the Executive Board. He is also the founder of Talix Therapeutics and Chief Executive Officer of BliNK Biomedical. Previously, he served as co-founder and Chief Executive Officer of Amakem Therapeutics where, under his leadership, Amakem developed a new class of glaucoma drug and managed the development up until phase 2b trials, after which the program was out-licensed to a Korean group. Dr. Elands was previously Chief Executive Officer of Vitec, Chief Business Officer of Silicos and VP of Business Development at Sidec AB. He started his pharmaceutical career at Marion Merrell Dow (later HMR and Aventis, now Sanofi). Dr. Elands holds a PhD in Neuropharmacology from the Rudolf Magnus Institute at University of Utrecht (Netherlands) and the CNRS INSERM Center for Pharmacology and Endocrinology in Montpellier (France).